Click Therapeutics’ migraine mobile app may now be used alongside standard drug therapies as a way to prevent episodic migraine in adults. In clinical trials, daily use of the app led to a statistically significant reduction in monthly migraine days.
Medicare’s physician fee schedule includes billing codes for digital therapeutics for the first time. Stakeholders say these codes could help turn around reimbursement challenges weighing on the entire digital medicines sector.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
Click Therapeutics is acquiring the assets of Better Therapeutics two months after that digital therapeutics developer announced it would lay off all employees and shut down. Better’s main asset is AspyreRx, an FDA-authorized mobile app for type 2 diabetes.
The Otsuka Pharmaceutical and Click Therapeutics mobile app Rejoyn received FDA clearance for use as an adjunct to medication in the treatment of major depressive disorder. But Otsuka must overcome hurdles facing digital therapeutics products, which have yet to gain traction among payers.
Digital therapeutics developer Click Therapeutics is partnering with Indivior to develop a mobile app for substance use disorder. Indivior is now Click’s third development partner, following deals with Boehringer Ingelheim and Otsuka Pharmaceutical.
Click Therapeutics is developing digital therapeutics for depression, insomnia and other conditions. It plans to use the funds to commercialize its therapeutics, through partnerships with pharmaceutical companies including Otsuka.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
Otsuka Pharmaceutical is partnering with Click Therapeutics to launch a remote clinical trial to evaluate the effectiveness of digital therapeutics in reducing depressive symptoms.
Otsuka's top U.S.-based leaders spoke about the company's partnerships in mental health and how it is driving innovation in big pharma.
In 2018 alone, ten companies have inked mega-deals of more than $100 million including Livongo, 23andMe and American Well.